Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mariana Pedrini is active.

Publication


Featured researches published by Mariana Pedrini.


Journal of Affective Disorders | 2016

Impaired glucose metabolism moderates the course of illness in bipolar disorder

Rodrigo B. Mansur; Lucas B. Rizzo; Camila M. Santos; Elson Asevedo; Graccielle R. Cunha; Mariane N. Noto; Mariana Pedrini; Maiara Zeni; Quirino Cordeiro; Roger S. McIntyre; Elisa Brietzke

BACKGROUNDnThe longitudinal course of bipolar disorder (BD) is highly heterogeneous, and is moderated by the presence of general medical comorbidities. This study aimed to investigate the moderating effects of impaired glucose metabolism (IGM) on variables of illness course and severity in a BD population.nnnMETHODSnFifty-five patients with BD were evaluated. All subjects were evaluated with respect to current and past psychiatric and medical disorders, as well as lifetime use of any medication. Body mass index (BMI) and metabolic parameters were obtained. IGM was operationalized as pre-diabetes or type 2 diabetes mellitus.nnnRESULTSnThirty (54.5%) individuals had IGM. After adjustment for age, gender, ethnicity, alcohol use, smoking, BMI and past and current exposure to psychotropic medications, individuals with IGM, when compared to euglycemic participants, had an earlier age of onset (RR: 0.835, p=0.024), longer illness duration (RR: 1.754, p=0.007), a higher number of previous manic/hypomanic episodes (RR: 1.483, p=0.002) and a higher ratio of manic/hypomanic to depressive episodes (RR: 1.753, p=0.028). Moreover, we observed a moderating effect of IGM on the association between number of mood episodes and other variables of illness course, with the correlation between lifetime mood episodes and frequency of episodes being significantly greater in the IGM subgroup (RR: 1.027, p=0.029). All associations observed herein remained significant after adjusting for relevant confounding factors (e.g. age, alcohol and tobacco use, exposure to psychotropic agents, BMI).nnnLIMITATIONSnCross-sectional design, small sample size.nnnCONCLUSIONSnComorbid IGM may be a key moderator of illness progression in BD.


Bipolar Disorders | 2016

Brain‐derived neurotrophic factor, impaired glucose metabolism, and bipolar disorder course

Rodrigo B. Mansur; Camila M. Santos; Lucas B. Rizzo; Elson Asevedo; Graccielle R. Cunha; Mariane N. Noto; Mariana Pedrini; Maiara Zeni-Graiff; Quirino Cordeiro; Maj Vinberg; Flávio Kapczinski; Roger S. McIntyre; Elisa Brietzke

OBJECTIVESnThe neurotrophin brain-derived neurotrophic factor (BDNF) has been proposed as a potential biomarker in bipolar disorder (BD). However, current evidence is limited and results have been highly heterogeneous. This study aimed to assess the moderating effect of impaired glucose metabolism (IGM) on plasma levels of BDNF in individuals with BD, and on the relationship between BDNF and variables of illness course.nnnMETHODSnWe measured and compared the plasma levels of BDNF in individuals with BD (n=57) and healthy controls (n=26). IGM was operationalized as pre-diabetes or type 2 diabetes mellitus. Information related to current and past psychiatric/medical history, as well as prescription of pharmacological treatments was also captured.nnnRESULTSnIndividuals with BD had lower levels of BDNF, relative to healthy controls, after adjustment for age, gender, current medications, smoking, alcohol use, and IGM (P=.046). There was no effect of IGM (P=.860) and no interaction between BD diagnosis and IGM (P=.893). Peripheral BDNF levels were positively correlated with lifetime depressive episodes (P<.001), psychiatric hospitalizations (P=.001) and suicide attempts (P=.021). IGM moderated the association between BDNF and the number of previous mood episodes (P<.001), wherein there was a positive correlation in euglycemic participants and a negative correlation in individuals with IGM.nnnCONCLUSIONSnBD is independently associated with lower levels of BDNF; IGM may modify the relationship between BDNF and BD course, suggesting an interactive effect of BDNF with metabolic status on illness progression.


Psychiatry Research-neuroimaging | 2015

Serum brain-derived neurotrophic factor and cortical thickness are differently related in patients with schizophrenia and controls

André Zugman; Mariana Pedrini; Ary Gadelha; Matthew J. Kempton; Cristiano Noto; Rodrigo B. Mansur; Marcos Leite Santoro; Clarissa Severino Gama; Rodrigo Affonseca Bressan; Philip McGuire; Andrea Parolin Jackowski; Elisa Brietzke

Brain-derived neurotrophic factor (BDNF) has been implicated in neuronal plasticity, a key process related to the pathophysiology of schizophrenia. However, the relationship of peripheral levels of BDNF to cortical thickness and subcortical structures has not been extensively investigated. This study aims to investigate the relationship of peripheral serum BDNF levels to cortical thickness and volumes of the hippocampus and amygdala. Twenty-nine patients with schizophrenia and 32 healthy controls were included in this study. Structural magnetic resonance imaging (MRI) scans obtained in a 1.5 T scanner were performed in all subjects. Images were processed using Freesurfer software. Blood samples were collected on the same day of the MRI scan for BDNF peripheral levels. Vertex-wise analysis revealed significantly thinner cortex in patients compared with controls. BDNF levels and cortical thickness showed different patterns of correlation for patients and healthy controls in one cluster in the right hemisphere distributed across the supramarginal, postcentral, and inferior frontal cortices.


Revista Brasileira de Psiquiatria | 2016

Challenges and developments in research of the early stages of bipolar disorder.

Elisa Brietzke; Adriane Ribeiro Rosa; Mariana Pedrini; Mariane N. Noto; Flávio Kapczinski; Jan Scott

Recently, attention in the field of bipolar disorder (BD) has focused on prevention, including early detection and intervention, as these strategies have the potential to delay, lessen the severity, or even prevent full-blown episodes of BD. Although knowledge of the neurobiology of BD has advanced substantially in the last two decades, most research was conducted with chronic patients. The objective of this paper is to comprehensively review the literature regarding the early stages of BD, to explore recent discoveries on the neurobiology of these stages, and to discuss implications for research and clinical care. The following databases were searched: PubMed, PsycINFO, Cochrane Library, and SciELO. Articles published in English from inception to December 2015 were retrieved. Several research approaches were used, including examination of offspring studies, retrospective studies, prospective studies of clinical high-risk populations, and exploration of the progression after the first manic episode. Investigations with neuroimaging, cognition assessments, and biomarkers provide promising (although not definitive) evidence of alterations in the neural substrate during the at-risk stage. Research on BD should be expanded to encompass at-risk states and aligned with recent methodological progress in neuroscience.


Journal of Psychiatric Research | 2016

Bipolar disorder course, impaired glucose metabolism and antioxidant enzymes activities: A preliminary report

Rodrigo B. Mansur; Lucas B. Rizzo; Camila M. Santos; Elson Asevedo; Graccielle R. Cunha; Mariane N. Noto; Mariana Pedrini; Maiara Zeni-Graiff; Eduardo Sauerbronn Gouvea; Quirino Cordeiro; Eva Z. Reininghaus; Roger S. McIntyre; Elisa Brietzke

This study aimed to examine the role of oxidative stress in bipolar disorder (BD) by evaluating the relationship among antioxidant enzymes activities, impaired glucose metabolism (IGM) and illness course. We measured the activities of plasma superoxide dismutase (SOD) and glutathione peroxidase (GPx) in individuals with BD (Nxa0=xa055) and healthy controls (Nxa0=xa028). Information related to current and past psychiatric/medical history, as well as prescription of any pharmacological treatments was captured. Impaired glucose metabolism was operationalized as pre-diabetes or type 2 diabetes mellitus. Our results showed that, after adjustment for age, gender, alcohol use, smoking and current medication, both BD (pxa0<xa00.001) and IGM (pxa0=xa00.019) were associated with increased GPx activity, whereas only BD was associated with decreased SOD activity (pxa0=xa00.008). We also observed an interaction between BD and IGM on SOD activity (pxa0=xa00.017), whereas the difference between BD and controls was only significant in individuals with IGM (pxa0=xa00.009). IGM, GPx and SOD activity were independently associated with variables of illness course. Moreover, IGM moderated the association between SOD activity and number of mood episodes (pxa0<xa00.001), as a positive correlation between SOD activity and mood episodes was observed only in participants with IGM. In conclusion, BD and IGM are associated with independent and synergistic effects on markers of oxidative stress. The foregoing observations suggest that the heterogeneity observed in previous studies evaluating antioxidant enzymes in BD may be a function of concurrent IGM; and that imbalances in the oxidative system may subserve the association between BD and IGM, as well as its relationship with illness course.


Schizophrenia Research | 2017

Metabolomics and lipidomics analyses by 1H nuclear magnetic resonance of schizophrenia patient serum reveal potential peripheral biomarkers for diagnosis

Ljubica Tasic; João Guilherme M. Pontes; Michelle S. Carvalho; Guilherme Cruz; Carolines Dal Mas; Sumit Sethi; Mariana Pedrini; Lucas B. Rizzo; Maiara Zeni-Graiff; Elson Asevedo; Acioly L.T. Lacerda; Rodrigo Affonseca Bressan; Ronei J. Poppi; Elisa Brietzke; Mirian A.F. Hayashi

Using 1H NMR-based metabolomics in association to chemometrics analysis, we analyzed here the metabolic differences between schizophrenia patients (SCZ) compared to healthy controls (HCs). HCs and SCZ patients underwent clinical interview using the Structured Clinical Interview for DSM Disorders (SCID). SCZ patients were further assessed by Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale, Global Assessment of Functioning Scale (GAF), and Clinical Global Impressions Scale (CGI). Using the principal component analysis (PCA) and supervised partial least-squares discriminate analysis (PLS-DA) in obtained NMR data, a clear group separation between HCs and SCZ patients was achieved. Interestingly, all metabolite compounds identified as exclusively present in the SCZ group, except for the gamma-aminobutyric acid (GABA), were never previously associated with mental disorders. Although the initial perception of an absence of obvious biological link among the different key molecules exclusively observed in each group, and no identification of any specific pathway yet, the present work represents an important contribution for the identification of potential biomarkers to inform diagnosis, as it was possible to completely separate the affected SCZ patients from HCs, with no outliers or exceptions. In addition, the data presented here reinforced the role of the modulation of glycolysis pathway and the loss of GABA interneuron/hyperglutamate hypothesis in SCZ.


Bipolar Disorders | 2016

Inter-relation between brain-derived neurotrophic factor and antioxidant enzymes in bipolar disorder.

Rodrigo B. Mansur; Camila M. Santos; Lucas B. Rizzo; Graccielle R. Cunha; Elson Asevedo; Mariane N. Noto; Mariana Pedrini; Maiara Zeni; Quirino Cordeiro; Roger S. McIntyre; Elisa Brietzke

Accumulating evidence indicates that oxidative stress and neurotrophins have a bidirectional relationship. In this post hoc, exploratory analysis, we investigated the association between plasma brain‐derived neurotrophic factor (BDNF) levels and activities of the antioxidant enzymes glutathione peroxidase (GPx) and superoxide dismutase (SOD) in individuals with bipolar disorder (BD) and healthy controls.


Psychiatry and Clinical Neurosciences | 2017

Plasma copeptin and metabolic dysfunction in individuals with bipolar disorder

Rodrigo B. Mansur; Lucas B. Rizzo; Camila M. Santos; Elson Asevedo; Graccielle R. Cunha; Mariane N. Noto; Mariana Pedrini; Maiara Zeni-Graiff; Quirino Cordeiro; Roger S. McIntyre; Elisa Brietzke

This study aimed to compare plasma copeptin levels, the c‐terminal of provasopressin, between individuals with bipolar disorder (BD) and healthy controls and to assess the relation between copeptin and metabolic parameters.


International Journal of Bipolar Disorders | 2017

1H-NMR, 1H-NMR T2-edited, and 2D-NMR in bipolar disorder metabolic profiling

Sumit Sethi; Mariana Pedrini; Lucas B. Rizzo; Maiara Zeni-Graiff; Caroline Dal Mas; Ana Cláudia Cassinelli; Mariane N. Noto; Elson Asevedo; Quirino Cordeiro; João Guilherme M. Pontes; Antonio Jadson Marreiro Brasil; Acioly L.T. Lacerda; Mirian A.F. Hayashi; Ronei J. Poppi; Ljubica Tasic; Elisa Brietzke

BackgroundThe objective of this study was to identify molecular alterations in the human blood serum related to bipolar disorder, using nuclear magnetic resonance (NMR) spectroscopy and chemometrics.MethodsMetabolomic profiling, employing 1H-NMR, 1H-NMR T2-edited, and 2D-NMR spectroscopy and chemometrics of human blood serum samples from patients with bipolar disorder (nxa0=xa026) compared with healthy volunteers (nxa0=xa050) was performed.ResultsThe investigated groups presented distinct metabolic profiles, in which the main differential metabolites found in the serum sample of bipolar disorder patients compared with those from controls were lipids, lipid metabolism-related molecules (choline, myo-inositol), and some amino acids (N-acetyl-l-phenyl alanine, N-acetyl-l-aspartyl-l-glutamic acid, l-glutamine). In addition, amygdalin, α-ketoglutaric acid, and lipoamide, among other compounds, were also present or were significantly altered in the serum of bipolar disorder patients. The data presented herein suggest that some of these metabolites differentially distributed between the groups studied may be directly related to the bipolar disorder pathophysiology.ConclusionsThe strategy employed here showed significant potential for exploring pathophysiological features and molecular pathways involved in bipolar disorder. Thus, our findings may contribute to pave the way for future studies aiming at identifying important potential biomarkers for bipolar disorder diagnosis or progression follow-up.


Molecular Neurobiology | 2018

Accessing Gene Expression in Treatment-Resistant Schizophrenia

Patricia Natalia Moretti; Vanessa Kiyomi Ota; Eduardo Sauerbronn Gouvea; Mariana Pedrini; Marcos Leite Santoro; Fernanda Talarico; Leticia Maria Spindola; Carolina Muniz Carvalho; Cristiano Noto; Gabriela Xavier; Elisa Brietzke; Ary Gadelha; Rodrigo Affonseca Bressan; Jair de Jesus Mari; Sintia Iole Belangero

Schizophrenia (SCZ) is a mental disorder arising from a complex interaction of genetic and environmental factors. It has been suggested that treatment-resistant schizophrenia (TRS) is a distinct, more severe, and homogenous subgroup of schizophrenia that could present specific biological markers. Our aim was to characterize expression of target genes in blood of TRS patients compared with non-TRS (NTRS) patients and healthy controls (HC). TRS has been defined using failure to respond to two previous antipsychotic trials. We hypothesized that genes involved in neurodevelopment, myelination, neuroplasticity, neurotransmission, and miRNA processing could be involved in treatment resistance; then, we investigated 13 genes related to those processes in 256 subjects, being 94 healthy controls and 162 schizophrenia patients treated with antipsychotics. Of those, 78 were TRS patients and 84 were NTRS patients. Peripheral blood samples were collected from all subjects and RNA was isolated. Gene expression analysis was performed using the TaqMan low-density array (TLDA) technology. To verify the influence of expression quantitative trait loci (eQTLs), we evaluated single-nucleotide polymorphism (SNP) of all genes using data from GTEx Project. SNP genotypes were obtained from HumanOmniExpress BeadChip. We did not detect gene expression differences between TRS and NTRS subjects, indicating candidate genes specific to treatment resistance. We detected an upregulation of CNR1 and UFD1L gene expression in patients (TRS and NTRS groups) when compared to controls, that may be associated with the release of neurotransmitters, which can influence neuronal plasticity, or with a stress response-activating protein degradation. DICER1 and AKT1 expression increased slightly across the groups and could differentiate only the extreme opposite groups, HC and TRS. Both genes act in heterogeneous pathways, such as cell signaling and miRNA processing, and seem to have an increased demand in the TRS group. We did not detect any eQTLs in our sample that could explain differences in mRNA levels, suggesting a possible regulation by other mechanism, not driven by genotypes. Our data strengthen the importance of several biological pathways involved in the schizophrenia refractoriness and severity, adding knowledge to develop more effective treatments in the future.

Collaboration


Dive into the Mariana Pedrini's collaboration.

Top Co-Authors

Avatar

Elisa Brietzke

University Health Network

View shared research outputs
Top Co-Authors

Avatar

Lucas B. Rizzo

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Elson Asevedo

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Mariane N. Noto

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Quirino Cordeiro

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Maiara Zeni-Graiff

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Camila M. Santos

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Graccielle R. Cunha

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge